76006-33-2 Usage
Chemical Properties
White to orange or brown powder
Uses
Different sources of media describe the Uses of 76006-33-2 differently. You can refer to the following data:
1. 3-Bromo-2-methylbenzoic Acid is a disubstituted benzoic acid used in the preparation of various biologically active compounds such as α-2 adrenoceptor agonists, Smootherned receptor anatogonists and H
IV-1 entry inhibitors.
2. 3-Bromo-2-methylbenzoic Acid is a disubstituted benzoic acid used in the preparation of various biologically active compounds such as α-2 adrenoceptor agonists, Smoothened receptor anatogonists and HIV-1 entry inhibitors.
3. 3-Bromo-2-methylbenzoic acid may be used to synthesize 4-(bromoacetyl)isoindolin-1-one and isocoumarins.
Check Digit Verification of cas no
The CAS Registry Mumber 76006-33-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,6,0,0 and 6 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 76006-33:
(7*7)+(6*6)+(5*0)+(4*0)+(3*6)+(2*3)+(1*3)=112
112 % 10 = 2
So 76006-33-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H7BrO2/c1-5-6(8(10)11)3-2-4-7(5)9/h2-4H,1H3,(H,10,11)
76006-33-2Relevant articles and documents
MALT1 MODULATORS AND USES THEREOF
-
Paragraph 00120; 00156, (2021/07/10)
Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.
BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY
-
Paragraph 0673; 0674; 0675, (2020/05/21)
The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM
-
Paragraph 0273; 0274, (2015/11/10)
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear
